Abstract Nesiritide and dopamine have been recognized for some time as potential renal adjunct therapies in the management of patients with acute heart failure (AHF). Several studies have yielded conflicting evidence of the efficacy of both medications in enhancing the renal function of patients with AHF. The Renal Optimization Strategies Evaluation (ROSE) study was a multicenter double-blind placebo controlled trial designed to assess the potential renoprotective effects of lowdose nesiritide and dopamine in AHF patients with renal dysfunction. This article will focus on previous research, summary of results, and lessons learned from the ROSE-AHF trial as well as future directions for clinical research and applications.
Introduction
Acute heart failure (AHF) is an increasingly widely recognized cause of hospital admission in patients aged 65 and over. Presently, approximately 5.1 million Americans over the age of 18 have heart failure. By 2030, this figure is expected to increase to over 8 million, with projected costs increasing from $30.7 billion to $69.7 billion [1] . Studies have suggested a definitive link between renal dysfunction and the prognosis of heart failure, with a recent meta-analysis demonstrating worsening renal function associated with increased mortality and hospitalization in patients with heart failure [2] , including those with heart failure with preserved ejection fraction [3, 4] . Given the growing prevalence and financial burden of heart failure in the United States, it has become increasingly important to identify strategies to achieve decongestion while preserving renal function in cases of AHF with associated renal dysfunction [5••] .
Over the past decade, there have been several trials studying the effects of either dopamine or nesiritide in conjunction with traditional diuretics for patients with AHF (Table 1) , and these trials have not provided sufficient evidence to justify the routine use of either drug in combination with standard therapies. The 2013 ACCF/AHA guideline for the management of heart failure concluded that low-dose dopamine infusion may be considered in addition to loop diuretic therapy to improve diuresis and better preserve renal function and renal blood flow, but acknowledged the lack of data supporting the efficacy of this intervention. Similarly, the guidelines provided a Class IIb recommendation for the use of vasodilators such as nitroglycerin, nitroprusside, or nesiritide for the relief of dyspnea in conjunction with intravenous diuretics in patients with AHF with no evidence of symptomatic hypotension [6••] .
Dopamine and Renal Function in AHF
Given the need for preserving renal function in patients with AHF, dopamine has been evaluated for its clinical utility in the hospital setting, with studies investigating the effect of varying doses on renal function and cardiac output. Dopamine has been observed to exert a graded pharmacological response, with dose-dependent effects on dopaminergic, beta (β) receptors, and alpha (α) receptors. It is recognized that at low doses of ≤3 μg/Kg/min, dopamine tends to activate A1 dopaminergic receptors, causing vasodilation of renal arteries and other vascular beds such as mesenteric, coronary, and cerebral regions. Additionally, A2 dopaminergic receptor activation causes reduction in the release of norepinephrine from sympathetic terminals, leading to increased vasodilation and renal blood flow (RBF). At an infusion rate of 3 to 5 μg/Kg/min, the activation of β1 and β2 adrenergic confers an inotropic effect of dopamine, leading to increased myocardial contractility and cardiac output [7] . When infused at >5 μg/kg/min, dopamine exerts its effects on α1 and α2 receptors, leading to systemic vasoconstriction, theoretically reducing renal blood flow [7] .
In the late 1990s, two small single-center open-label studies revealed a potential renoprotective effect of low-dose dopamine in combination with diuretics during aggressive diuresis in patients with AHF [8, 9] . Renal function (measured by BUN, serum creatinine, creatinine clearance, and urine output) was improved in a study of 20 AHF patients receiving dopamine (2 μg/Kg/min) with bumetanide as compared to bumetanide alone [9] . A similar study by Cotter et al. in 20 patients with AHF revealed that the patients who received low-dose dopamine (4 μg/Kg/min) in conjunction with lowdose (80 mg/day) oral furosemide experienced an improvement in renal function (measured by creatinine clearance), reduced incidence of hypokalemia, and preservation of mean arterial pressure (MAP) as compared to patients who received either low-dose dopamine plus high-dose furosemide or highdose furosemide alone [8] . It is important to note that the aforementioned studies used variable doses of dopamine, creating difficulty in assessing the efficacy and side-effects profile of this compound.
More recently, the DAD-HF I and II trials further investigated the use of dopamine in AHF. DAD-HF I compared high-dose furosemide plus "low-dose" (5 μg/Kg/min) dopamine infusion to high-dose furosemide alone, and found no significant differences in 60-day mortality or rehospitalization rates, but did demonstrate improved potassium homeostasis and preservation of renal function [10••] . DAD-HF II studied both low-and high-dose furosemide in relation to low-dose furosemide with "low-dose" (5 μg/Kg/min) dopamine [11••] . There were no significant differences in 60-day and one-year all-cause mortality rate, hospitalization for heart failure, or overall dyspnea relief between treatment groups. Notably, there was a higher incidence of worsening renal failure in the high-dose furosemide group compared to the other treatment arms. The trial was terminated early due to tachycardia noted in the "low-dose" dopamine + furosemide treatment arm. It is important to note that the dose of dopamine used in both DAD-HF trials (5 μg/Kg/min) was a level at which the inotropic effects of the medication predominate [7, 12] .
Nesiritide and Renal Function in AHF
Brain natriuretic peptide (BNP) is a cardiac peptide with vasodilating, renin-inhibiting, natriuretic, and diuretic properties [13] . Human recombinant BNP (nesiritide) has been approved by the FDA since 2001 for the management of AHF [14] . The standard recommended dose of nesiritide is a bolus of 2 μg/kg followed by infusion of 0.01 μg/kg/min [15] . The BNP-CARDS study explored the renal effects of nesiritide infusion (0.01 μg/Kg/min with or without a 2-μg/ Kg bolus) over 48 hours, along with usual clinical care, compared to placebo for the treatment of patients with AHF and renal dysfunction. The study revealed no significant differences between treatment groups in the incidence of 20 % or greater rise in creatinine level, weight change, or 30-day death/hospital readmission rates. There was a non-significant trend for study drug discontinuation in the nesiritide group due to hypotension (13 % vs. 6 %), with lower blood pressures overall in this group. Overall, nesiritide conferred no renal protective effect in AHF patients with renal dysfunction [16] . A similar study was conducted at the Mayo Clinic, where 71 patients with AHF and underlying renal dysfunction were randomized to nesiritide at standard infusion (2-μg/kg bolus; 0.01 μg/Kg/min for 48 hours) or placebo in addition to standard heart failure therapy. Patients randomized to the nesiritide treatment arm had smaller increases in creatinine (p=0.048) and BUN (P=0.02). They were noted to have greater reductions in blood pressure at 24 hours but not at 48 or 72 hours [17] . Overall, however, there were no significant changes in diuretic responsiveness as measured by weight change and fluid balance. Additionally, there was no significant reduction in aldosterone or angiotensin II levels, and BNP remained relatively unchanged between treatment arms. The authors concluded that adjuvant nesiritide treatment may have conferred mild benefit in renal function, but did not increase diuretic responsiveness or help to prevent activation of the RAAS [17] .
Lastly, the ASCEND-HF trial studied the use of similar nesiritide infusions in over 7,000 patients with AHF. The study revealed no significant changes in death or rehospitalization, and no changes in renal function at various time points. Interestingly, there was a mild improvement in subjective symptoms of dyspnea at six hours with nesiritide, but it did not reach a level of statistical significance over the course of the study. The ASCEND study did not demonstrate significant renal protective effects. Additionally, there was a significant increase in the incidence of symptomatic and asymptomatic hypotension in the nesiritide group as compared to placebo [18, 19••] .
Preclinical studies have demonstrated the renal-enhancing effects of systemic nesiritide infusion, but these results have not been replicated in formal clinical trials. The discrepancy between preclinical and clinical data may be due to the fact that clinical studies have used a higher dose of nesiritide, predisposing to systemic hypotension, which could then negate the renal-enhancing effects of the drug [20] .
ROSE-AHF Study
The ROSE AHF trial used a novel design to evaluate two renal optimization strategies in patients with AHF and renal dysfunction, testing the effects of either low-dose nesiritide or dopamine on enhancing decongestion while preserving renal function. The primary endpoints were 72-hour cumulative urine volume and change in serum cystatin C from enrollment to 72 hours as a measurement of renal function preservation [5••, 21] .
The ROSE study included subjects aged 18 and over, hospitalized for the treatment of AHF with renal dysfunction (glomerular filtration rate [GFR] of 15-60 mL/min/1.73 m 2 as estimated by the Modification of Diet in Renal Disease equation), and enrolled within 24 hours of admission. In order to minimize the number of patients requiring central line placement for dopamine administration, participants were initially randomized 1:1 in an open-label fashion to the nesiritide or dopamine strategies. Patients who were in the dopamine strategy were randomly assigned in a 2:1 ratio to low-dose dopamine infused at 2 μg/kg/min for 72 hours versus placebo. Patients in the nesiritide strategy were randomized in a 2:1 ratio to low-dose nesiritide (0.005 μg/kg/min) over 72 hours or placebo. All patients received IV furosemide treatment at 2.5 times the equivalent of oral outpatient dosing for the first 24 hours.
Results
A total of 360 patients across 26 sites in North America were enrolled. The median age of the study population was 70 years, median ejection fraction was 33 %, and the patients had moderate to severe renal dysfunction, with a median estimated GFR of 42 ml/min/1.73 m 2 . Overall, there were no significant differences in either the co-primary endpoints of 72-hour cumulative urine volume or change in cystatin-C from baseline to 72 hours when comparing low-dose dopamine or lowdose nesiritide to placebo. Furthermore, there were no significant differences between the groups in other secondary endpoints assessing for decongestion or renal function, such as change in plasma creatinine, weight, NT-proBNP from baseline to 72 hours, and dyspnea visual analog scale area under the curve from randomization to 72 hrs. At 60 days, there were also no significant differences between either treatment group compared to placebo in terms of death, serious adverse events, or heart failure-related visits or hospitalization. There were also no significant differences between treatment groups versus placebo in mortality at 180 days.
Safety and Tolerability
Patients in the nesiritide arm experienced higher rates of treatment failure, primarily due to drug discontinuation secondary to hypotension. This is similar to previous studies, namely ASCEND-HF, which noted greater prevalence of asymptomatic or symptomatic hypotension with the study drug [19••] . Compared to the placebo group, dopaminetreated patients were more likely to have the study drug discontinued due to tachycardia. Overall, the study demonstrated that in patients with AHF and moderate to severe renal dysfunction, neither low-dose nesiritide nor low-dose dopamine enhanced decongestion or improved renal function in conjunction with a standard diuretic.
Subgroup Analysis
Subgroup analyses suggest a trend for differential treatment effects according to ejection fraction. The 72-hour cumulative urine volume tended to be lower with low-dose dopamine as compared to placebo in subgroups of patients with higher ejection fraction. With low-dose nesiritide, the 72-hour cumulative urine volume tended to be higher, and there was a trend toward less increase in cystatin C from baseline to 72 hours as compared to placebo in the subgroup of patients with lower ejection fraction.
Lessons Learned from ROSE AHF

Potential Differential Responses in AHF with Reduced Versus Preserved Ejection Fraction
AHF is a heterogeneous entity with multiple underlying causes, and can be broadly classified based on either reduced or preserved left ventricular ejection fraction (LVEF). AHF with reduced LVEF is characterized by impaired contractile function, leading to impaired cardiac output and subsequent tissue perfusion. AHF with preserved LVEF, on the other hand, is secondary to impaired ventricular relaxation, leading to reduced filling, increased filling pressure, and impaired cardiac output [22] . Previous studies have revealed that AHF with preserved LVEF comprises as much as 50 % of all cases of AHF [23] . Patients with AHF and preserved LVEF tend to be older, female, and have hypertension, but are less likely to have a history of myocardial infarction, as compared to those with reduced LVEF. Importantly, recent data suggest that mortality rates and rates of rehospitalization do not differ significantly between reduced and preserved LVEF groups [24] . In an elegant study, Schwartzenberg et al. investigated acute hemodynamic responses to vasodilation with intravenous sodium nitroprusside in patients with HF and reduced LVEF to those with HF and preserved LVEF [25] . Patients with HF with preserved LVEF demonstrated greater blood pressure reduction and increased likelihood of stroke volume reduction in response to vasodilators, which suggests fundamental physiological differences between the two HF phenotypes in response to vasodilators. Subgroup analyses of the ROSE AHF study suggest a trend in patients with HF and reduced LVEF toward more favorable responses to both lowdose dopamine and nesiritide as compared to patients with preserved LVEF. With low-dose dopamine, the 72-hour cumulative urine volume trended higher in patients with reduced LVEF as compared to placebo. Similarly, with low-dose nesiritide, patients with reduced LVEF demonstrated a trend toward greater 72-hour cumulative urine volume, with lower increases in cystatin C from baseline to 72 hours as compared to placebo. As stated by the authors, one of the limitations of the ROSE AHF study was that it was not powered to detect differences in the subgroups. A review of the literature to date reveals no significant clinical trials studying the differential effect of AHF therapies on patients with reduced versus preserved LVEF. Future studies in AHF should be designed and powered to separately target patients with reduced LVEF or preserved LVEF.
Use of Low-Dose Dopamine in AHF Despite previous studies suggesting that low-dose dopamine may have renal-specific protective actions and may enhance renal blood flow, the ROSE AHF study demonstrated that low-dose dopamine at 2 μg/Kg/min did not enhance decongestion or preserve renal function in patients with AHF and renal dysfunction. Importantly, the study also demonstrated that this low dose is not renal-specific in all patients, which is supported by the fact that patients in the dopamine group were more likely to have the study drug discontinued due to secondary tachycardia and less likely to develop hypotension as compared to placebo. One of the lessons learnt from the ROSE AHF study was that the routine use of low-dose dopamine in addition to diuretics in patients with AHF and renal dysfunction did not enhance decongestion or preserve renal function. Does this mean that there is no role whatsoever for dopamine in the management of AHF? In view of the fact that the ROSE AHF study evaluated the routine and upfront use of low-dose dopamine within 24 hours of admission, it may still be reasonable to consider the use of low-dose dopamine in patients with AHF who develop worsening renal function or diuretic resistance. Furthermore, as the ROSE AHF study only enrolled patients with systolic blood pressure greater than 90 mmHg, dopamine may still have a role in the treatment of AHF in patients with systolic blood pressure less than 90 mmHg. The 2013 ACCF/AHA guidelines for the management of heart failure provide the following Class IIb recommendation: short-term, continuous intravenous inotropic support may be reasonable for hospitalized patients presenting with documented severe systolic dysfunction, low blood pressure, and significantly depressed cardiac output to maintain systemic perfusion and to preserve end-organ performance [6••] . It is clear, therefore, that the use of dopamine in AHF should be on an individualized basis.
Use of Low-Dose Nesiritide in AHF
Notwithstanding preclinical studies that established favorable renal effects of nesiritide, the ASCEND trial demonstrated that while the use of nesiritide in AHF at the approved recommended dose was safe, it did not enhance renal function. The ROSE AHF trial studied nesiritide at a lower dose with the rationale that there would be less hypotension and more renal-specific therapeutic effects. However, systemic effects were still noted even at the reduced dose, as evidenced by the increased risk of hypotension in the nesiritide treatment arm. While the results of ROSE AHF provided no significant support with regard to renal sparing effects for the routine and upfront use of low-dose nesiritide infusion in the treatment of AHF patients with renal dysfunction, the role of lowdose nesiritide in patients with AHF who develop worsening renal function or diuretic resistance remains undetermined.
Conclusions
There is a clear need for renal-targeted therapies in patients with AHF and associated renal dysfunction. While the ROSE-AHF trial did not yield answers regarding definitive treatment for these patients, it did shed light on the heterogeneous nature of AHF by demonstrating that therapies for AHF cannot be broadly applied to a syndrome with such a multifaceted pathology. Both compounds may warrant further investigation in dedicated clinical trials involving AHF patients with reduced LVEF. In the meantime, clinicians still have a degree of latitude in choosing medical therapies for patients with diuretic-resistant AHF or AHF with hypotension, with options that still include either dopamine or nesiritide.
